Embecta (EMBC) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$1.0B

Revenue (quarter)

$271.7M

Revenue growth (year over year)

−8.05%

Gross profit (trailing twelve months)

$601.3M

Gross margin

59.03%

Net income (trailing twelve months)

$87.5M

Net income (quarter)

$21.1M

Net income growth (year over year)

−53.63%

Net margin

8.59%

Return on equity

—

EPS (trailing twelve months)

$1.50

Book value per share

−$10.81

P/E (trailing twelve months)

3.88

Price to book

—

Debt to assets

148.42%

Payout ratio

36.67%

Dividend yield

5.55%

Company profile

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

• Is Embecta (EMBC) profitable?

  Yes. Embecta earned $87.5M in net income over the trailing twelve months, a net margin of 8.59%.

• How much revenue does Embecta (EMBC) make?

  Embecta generated $1.0B in revenue over the trailing twelve months, down 8.05% year over year.

• What is EMBC's P/E ratio?

  Embecta trades at 3.9 times trailing twelve-month earnings, on an EPS of $1.50.

• How do I buy stock in Embecta (EMBC)?

  EMBC trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.